Document:

EX-10.13

 Exhibit 10.13 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 

 

 CONFIDENTIAL 
  

					
	Xeris/Bachem	  	Quality Assurance Agreement	  	

 This Quality Assurance Agreement (the “Quality Assurance Agreement”) is made as of November 20,
2015 (“Effective Date”) between Bachem AG, an entity organized under the laws of Switzerland, with its principal place of business at Hauptstrasse 144, CH-4416 Bubendorf, Switzerland
(“Bachem”), and Xeris Pharmaceuticals, Inc. an entity organized under the laws of Texas with its principal place of business at 3208 Red River Street, Suite 300, Austin, TX 78705, USA (“Xeris”). 

PREAMBLE 
 WHEREAS,
Bachem is engaged in the business of manufacturing of active pharmaceutical ingredients (API) and has a broad proprietary know-how in the development of the manufacturing process for peptides including related
analytical methods as well as in the manufacturing of peptides: 
 WHEREAS, Xeris is a company engaged in research, development and
eventual commercialization and sate of medicinal products. 
 WHEREAS, the Parties now desire to set forth in this Quality Assurance
Agreement a plan, prepared by Xeris and Bachem, for determining the conformity of Product supplied by Bachem to Xeris under this Agreement to the Specifications (as defined below). 

NOW THEREFORE, in consideration of premises and mutual promises herein made, and in consideration of representations, warranties, and
covenants herein contained, Bachem and Xeris agree as follows: 
 ARTICLE 1 

PREAMBLE AND DEFINITIONS 

Section 1.1 Preamble. The preamble to this Quality Assurance Agreement forms an integral part hereof. 

Section 1.2 Definitions. Unless the context otherwise requires, the following terms as used in this Quality Assurance Agreement
shall have the following meaning: 
 “Annex” means an exhibit annexed lo and forming part of this Quality Assurance
Agreement. 
 “Competent Authorities” mean the FDA in the United States or any other applicable national,
supranational, federal, state or local regulatory agency or entity having the responsibility, jurisdiction, and authority to approve the clinical manufacture, use, importation, packaging, labeling, marketing, and sale of Product or Xeris’
Pharmaceutical Products in any country where Bachem has authorized Xeris to access Bachem’s DMF. 

  
 Page 1 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 

“Xeris’ Pharmaceutical Products” means Xeris’ pharmaceutical medications or formulations, including those in
any manner arising or resulting from the use of the Product in connection with the above medications. 
 “Certificate of
Analysis” means a certificate In writing for each batch of Product, signed by a Qualified Person or its deputy, that provides full analytical results of the batch of Product, a
TSE-Safely-Certificate and certifies (a) the conformity of the batch of Product to the Specifications and (b) that manufacturing and release records of the respective batch of Product were reviewed
by Bachem and manufacturing and release of the respective batch of Product is in accordance with all applicable cGMP requirements. All Product batches delivered to Xeris or its designee shall comply with provisions of this Quality Assurance
Agreement. 
 “Confidential Information” means, with respect to a Party, all information of a confidential nature
which may be disclosed by or on behalf of that Party to the other Party including, but not limited to, the Product Information and information relating to the disclosing Party’s business or scientific strategies, research, product development,
marketing, customers. Opportunities, finances, sales and pricing of products, processes, and all other written information clearly identified as “Confidential” when submitted by the disclosing Party to the receiving Party. 

“DMF” means Drug Master File maintained with the FDA or its equivalent maintained with a Competent Authority in any other
country mutually agreed between the Parties. 
 “GMP or cGMP” means the (a) current regulations for Good
Manufacturing Practice as outlined in the US Code of Federal Regulations and applicable FDA guidance documents as amended and (b) the ICH 07 guideline for the production and release of active substances and in EC Directive 2003/94/EC as amended
from time to time and transposed into the respective national laws at the member states of the European Union and the equivalent US (FDA) laws and regulations. 

“Latent Defect” means, with respect to Product, a hidden or latent defect not detected by the analytical test methods
in operation at the date of shipment to Xeris of the relevant Product by Bachem and which was not detected by Xeris during the initial Testing Period. 

“Manufacture” means the manufacture, processing, packing, or holding of a product including packaging and labelling
operations, testing, and quality control and QA release. 
 “Major Deviation” means a deviation with the potential
to have an impact on Product quality, safety, efficacy or stability. 
 “Minor Deviation” means any deviation that
will not have an impact on Product quality, safety, efficacy or stability. 
 “Major Change” means a change
that may adversely impact quality, safely, efficacy, stability, or regulatory compliance of the Product. Any change that will require regulatory authority approval is also defined as a Major Change. 

  
 Page 2 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 

“Minor Change” means a change that will not have any adverse impact on Product quality, safely, efficacy,
stability, or regulatory compliance, and will not require authority approval. 
 “OOS” means out of specification and, with
respect to a Product or testing of a Product, means that the Product does not conform to the Specifications or the results of testing of the Product indicate non-conformance of the Product to the
Specifications. 
 “Party” or “Parties” shall mean Bachem or Xeris, Individually or collectively as
the context requires. 
 “Product” means synthetically manufactured human Glucagon as described in more detail in
the Specifications in Annex 1 of this Quality Assurance Agreements non-sterile active pharmaceutical ingredient(s) in bulk form, manufactured under GMP requirements. 

“Qualified Person” has the meaning ascribed to it in EC Directive 2003/94/EEC as amended or as m any other applicable
GMP regulation. 
 “Specifications” means the specifications for the Product, as more specifically described in
Annex 1 of this Quality Assurance Agreement. Annex 1 may be modified from time to time by written amendment to this Quality Assurance Agreement in accordance with Section 12.4. 

“Testing Period” means the time after Xeris’ receipt of any shipment of Product to subject such Shipment, on a
sample basis, to quality control testing to determine conformity with the relevant Specifications (including COAs and COCs), and whether or not a Product is free from defects in workmanship or materials, and manufactured according to cGMP. 

“TSE-Safety-Certificate” means a certificate certifying that a batch of the
Products) complies with or is outside the scope of monograph 5.2.8 of the European Pharmacopeia. 
 “USP” means current
United States Pharmacopeia official compendia of standards. 
 “EP” means current European Pharmacopoeia official compendia
of standards. 
 Section 1.3 Interpretation. Words denoting the singular include the plural and vice versa, words denoting a
gender include all genders, and words denoting persons include corporations and all other legal entities. 
 ARTICLE 2 

SUBJECT OF THIS QUALITY ASSURANCE AGREEMENT 

Section 2.1 The purpose of this Quality Assurance Agreement is to define and to establish the obligations and responsibilities of Bachem
and Xeris relating to the quality assurance requirements of the manufacture, release and supply of the Product pursuant to the Agreement by Bachem in accordance with GMP guidelines tor active pharmaceutical ingredients (APIs), namely the US Code of
Federal Regulation, Parts 11, 210, 211, applicable 

  
 Page 3 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 

FDA guidance documents and ICH 07 GMP Guide for APIs as accepted and implemented by the national and international regulations of the European Community, the
United States of America, Japan and the member slates of the Pharmaceutical inspection Convention (PIC) scheme. 
 ARTICLE 3 

QUALITY ASSURANCE AGREEMENT CONTACT INFORMATION 

Section 3.1 Notices. Any notice, request, delivery, approval or consent required or permitted to be given under this
Quality Assurance Agreement shall be in writing and shall be deemed to have been sufficiently given if delivered in person, transmitted by telecopy with a confirming copy, by e-mail with a confirming copy,
sent by Overnight courier or registered mail to the Party to whom it is directed at its address shown in Section 3.02 and Section 3.03 or such other address as such Party shall have last given by notice 10 the other Party. 

Section 3.2 Notices to Bachem. Any notice to Bachem under this Quality Assurance Agreement shall be addressed to: 

Bachem AG, Hauptstrasse 144 
 4410
Bubendorf, Switzerland 
 [***] 

[***] 
 [***] 

[***] 
 Section 3.3
Notices to Xeris. Any notice to Xeris Shall be addressed to: 
 Xeris Pharmaceuticals Inc., 3208
Red River Street, Suite 300 
 Austin, TX 78705 

[***] 
 [***] 

[***] 
 ARTICLE 4 

THE PRODUCT 

Section 4.1 Product. The Product covered by this Quality Assurance Agreement, together with the related Specifications, is
listed in Annex 1. 
 ARTICLE 5 

SUPPLY AND MANUFACTURE 

Section 5.1 Premises and Subcontracting. Bachem will manufacture and release the Product at its Site in Bubendorf,
Switzerland. Bachem may subcontract quality control work provided that the respective contract laboratories have been qualified by Bachem. In case Bachem subcontracts any work. Bachem is solely responsible for the fulfillment of the obligations of
this Quality Assurance Agreement by its subcontractors Bachem agrees to only use qualified laboratory resources listed in Annex I Any modification to the approved contract laboratories list will require prior notice to Xeris. 

  
 Page 4 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 

Section 5.2 GMP Guidelines. The premises, equipment and systems used to manufacture and release the Product must be in
compliance with all applicable GMP requirements for APIs, including the principles detailed in the US Code of Federal Regulations, Parts 11, 210, 211, and ICH Q7 GMP Guide for APIs, as accepted and implemented by the national and international
regulations of the European Community, the United States of America, Japan and the member slates of the PIC scheme. 
 Section 5.3
Materials. Bachem shall be responsible for procuring all materials for manufacturing, release and supply of the Product. Bachem shall also be responsible for the specifications and the release of such materials. Upon Xeris’
request, Bachem shall provide access to such specifications and release documents for such materials to Xeris for review at Bachem’s Site in Bubendorf. 

Section 5.4 Manufacturing Batch Records. Bachem shall maintain the manufacturing process and method information in its own
formal in manufacturing batch records. COAs including a CoC in English shall be sent to Xeris in a PDF file or equivalent. 

Section 5.5 Manufacturing Process. Product must be manufactured, tested, released and packed in compliance with the
requirements of the provisions of this Quality Assurance Agreement and CGMPs. Any changes made to the established manufacturing process are subject to Bachem’s change control process as described in Article 7 of this Quality Assurance
Agreement hereunder. Xeris shall be notified in advance of any Major Changes associated with the manufacture and quality control of Product. 

Section 5.6 Facilities. Bachem shall manufacture the Product in facilities which are regularly monitored by Bachem to
demonstrate compliance with applicable cGMP guidelines and codes of practice for the type of production. 
 Section 5.7 Batch
Numbering. Bachem shall implement and use a unique batch numbering system for numbering each batch of Product. This number shall appear on all documents relating to the particular batch of Product. Bachem is responsible for maintaining an
associated lot genealogy, where the final lot number may be traced back to the intermediates and starting materials used in the specified batch. 

Section 5.8 Date of Manufacture. Bachem Shalt allocate the dale of manufacture as the dale when ail manufacturing work has
been completed and the batch is ready for release testing. Bachem shall ensure that stability and retest dates are aligned with Bachem’s assigned Date of Manufacture. 

Section 5.9 Re-Test Date. The re-test date
for Product shall be allocated based on the date of manufacture together with the retest period established by stability data generated using Product produced by the validated manufacturing process. 

Section 5.10 Rework and Reprocessing. Reprocessing and rework of Product is permitted with rework steps that have been
validated as part of the manufacturing process and in accordance with the provisions of the ICH Q7 guideline Bachem will notify Xeris prior to any reworking. 

  
 Page 5 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 

Section 5.11 Manufacturing and Equipment Data. Bachem shall be responsible for keeping records of equipment usage,
cleaning, raw material batch numbers and certification as well as in process results and parameters. Such documentation shall be retained by Bachem as described in Section 6.9 hereunder. 

Section 5.12 Training and Personnel. Bachem shall maintain a GMP compliant training program. Bachem will ensure and
document that employees have and maintain education, naming, and experience appropriate to their job duties. Bachem will not employ any person or GMP service provider listed in the DMF that has been debarred by any Competent Authorities or,
to Bachem’s knowledge, is currently under any investigation which could lead to such debarment. Bachem will provide upon request the required statement supporting the claim that none of the employees or service providers listed in the DMF have
been debarred or, to Bachem’s knowledge, are under investigation by any Competent Authorities. 
 Section 5.13 Drug Master
File. In mutually agreed countries, Bachem will maintain the Product DMF according to requirements defined by each local Competent Authority. Bachem will provide a letter to the specified Competent Authority at Xeris’ request in accordance
with Section 5.2 of the Agreement allowing such Competent Authority to review Bachem’s Product DMF relative to any Xeris submission. 

ARTICLE 6 
 QUALITY
ASSURANCE AND QUALITY CONTROL 
 Section 6.1 Sampling and Samples. Bachem shall ensure that representative samples of
Product are taken in accordance with GMP guidelines. Bachem will store API retention samples for all lots produced, sufficient to perform at least [***] full specification analyses, in containers that are equivalent to or more protective than the
commercial packaging in accordance with the applicable GMP guidelines API samples will be retained for a minimum of [***] as of batch release. These retain samples will not be specific to Xeris. Xeris shall retain sufficient samples of Product for
[***]. A quantity sufficient to perform [***] tests of Products shall be retained by Xeris. 
 Section 6.2 Testing of Raw
Materials. Bachem shall ensure that materials and packaging components used to manufacture the Product’s) are in compliance with the specifications as defined by Bachem and, if applicable, disclosed to Xeris for on-site review in Bubendorf. Reduced testing shall be permitted for vendors that have been formally qualified by Bachem and have a demonstrated history of meeting all test specifications, per an approved Bachem SOP.
In this case raw materials for use in the manufacture of the Product shall be tested at a minimum for identity on each shipment delivered. Bachem will store retention samples of all STARTING MATERIALS and IMTERMEDIATES used sufficient to perform at
least [***] full specification analyses and meaningful use tests, in containers that are equivalent to or more protective than the commercial packaging. In all cases, sample packaging and storage conditions shall maintain the physical and chemical
integrity of the sample. Samples are to be retained for [***]. However, there will be no retains (or compressed gasses and extremely hazardous materials. 

  
 Page 6 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 

Section 6.3 In-Process Testing. Bachem shall be responsible for ensuring that all
required in-process testing is completed using suitable methods, when applicable, and documented. This will include environmental controls where required. Bachem shall also be responsible for defining
appropriate tests and criteria. 
 Section 6.4 Specifications. Bachem shall implement Specifications for the
Product as mutually agreed in this Quality Assurance Agreement. It will remain the responsibility of Xeris to ensure that the Specifications are appropriate for The intended use of Product. 

Section 6.5 Approval to ship the Product. Bachem shall be responsible for ensuring that the Product conforms to the Specifications
and has been made and tested in accordance with the manufacturing procedure and with all provisions or this Quality Assurance Agreement This will be carried out by Bachem’s Qualified Person or deputy before any shipment of Product to Xeris.

 Section 6.6 Certificate of Analysis. Bachem shall issue a Certificate of Analysis serving as a confirmation that The
Product has been manufactured and tested in accordance with the GMP requirements and with all provisions of this Quality Assurance Agreement The Certificate of Analysis will be signed by Bachem’s Qualified Person or deputy and provide full
analytical results for each batch. It will be supplied with each delivery of each batch of Product. 
 Section 6.7 Release of
Product for use by Xeris. Bachem shall release Products under their quality system ensuring compliance with applicable regulations Release documentation shall accompany a CoA / CoC as described in this document. Xeris shall be responsible
for release of the Products for further use. Xeris shall alto be responsible for ensuring that all further medicinal use of Product is in accordance with the relevant laws and regulations. 

Section 6.8 Documentation. Bachem shall create and maintain complete manufacturing and control documentation that is at
minimum comprised of (i) a completed batch production record including m-process controls; and (ii) a completed analytical batch record; and (iii) equipment charts and print-cuts, and
(iv) any documentation on investigations, deviations, OOS or failures as applicable (v) employee training files and records to support manufacturing (vi) cleaning, maintenance and validation records lo support manufacturing. 

Section 6.9 Document Retention. Bachem shall retain all documentation relevant to the manufacture and release of the Product
securely and for a minimum of [***]. The documentation will be available to Xeris and Competent Authorities for on-site review at Bachem in Bubendorf. 

Section 6.10 Retained Samples. Bachem Shall retain sufficient samples of Product for [***] years after batch release A quantity
sufficient to perform at least [***] shall be retained. Xeris Shall retain Product samples as described in Section 6.1 above. 

Section 6.11 Stability Studies. Bachem will run stability testing under ICH conditions according to the relevant Bachem’s
SOP. 

  
 Page 7 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 

Section 6.12 Rejection of Product by Xeris. Any problem likely to cause rejection (excluding Latent Defects as defined
above) of Product shall promptly be notified to Bachem after It Is identified and in any event within [***] of receipt of Products by Xeris. 

Section 6.13 Reference Standards. Bachem will use a fully qualified internal reference standard which is qualified
according to expectations of Competent Authorities and as detailed in current guidance documents which may be amended from time to time. Bachem and Xeris will collaborate to consider implementation of USP methods and reference standard when
appropriate and practical. 
 Section 6.14 Conflict Resolution of Analytical Issues. In the event that a dispute arises
between Bachem and Xeris in the analysis of the Product, the resolution shall conform with GMP rules on OOS results and shall proceed in stages. The first stage requires direct communication between analytical experts from the Parties to determine
that the methods of analysis are the same and are being executed in the same manner at both sites. In a second stage, carefully controlled and split samples shall be exchanged to attempt to reach agreement. Should there be a failure to achieve a
common set of results, analytical experts from the Parties shall be required to meet to work through the analysis of a mutually agreed sample, if these actions fail to achieve a common set of results a qualified, independent, third party referee
laboratory shall be used to achieve resolution. This laboratory shall be selected mutually by the Parties. The results from this referee laboratory shall be binding on both Parties. Whatever the outcome, Xeris retains the right to decide whether the
Product will be used to manufacture Xeris’s Pharmaceutical Product. Nothing in this Section 6.14 shall be construed to limit Bachem’s or Xeris’ rights. 

Section 6.15 Conflict Resolution in Quality Assurance Issues. In the event that a dispute arises between Bachem and Xeris
concerning the acceptability of a batch of Product, the resolution shall proceed in stages The first stage requires direct communication between The responsible quality assurance personnel from the Parties to determine the facts of the matter and to
produce an investigation report. This report shall contain complete details of the problem together with any discussion on the validity and weight to be applied to any results The investigation report shall be reviewed by the senior quality
personnel from the Parties and the Parties shall determine together the action to lake It these actions fail to achieve resolution, a qualified, independent external quality consultant shall be used to decide the appropriate action This consultant
shall be selected mutually by the Parties. The results from this consultant shall be binding on both Parties. Whatever the outcome, Xeris retains the right to decide whether the Product will be used to manufacture Xeris’s Pharmaceutical
Product. Nothing in this Section 6.15 shall be construed to limit Bachem’s or Xeris’s rights. 
 Section 6.16
Right to Audit. Bachem shall allow representatives of Xeris to have access to is manufacturing, warehousing and laboratory premises and to the associated records including inspection reports, Bachem responses and corrective actions
generated from the inspection by any Competent Authority, related to Product or Quality Systems if adversely impacting quality and supply of Product and redacted as necessary to preserve the confidential information of third parties, with prior
written reasonable notice for audit purposes. Xeris shall follow Bachem systems and procedures to ensure the safety, confidentiality and security of 

  
 Page 8 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 

Bachem processes, facilities and personnel during any audit Responses to audit findings will be provided by Bachem within [***] of Bachem’s receipt of an
audit findings report from Xeris. Initial responses to critical observations that have the potential to impact safety, identity, strength purity or quality (SISPQ) of the Product will be provided to Xeris within [***]. 

Section 6.17 Audit Schedule. Without limiting Xeris’s rights, Bachem agrees to support Xeris audits according the following
schedule: 
  

	 	1.	[***] per year; 

  

	 	2.	[***] additional technical meeting associated with the NOA review as agreed between the parties; 

  

	 	3.	For cause audits may be conducted by Xeris with reasonable notice. 

 Section 6.18 Audit
of Competent Authorities. Bachem shall permit inspection by applicable Competent Authorities Bachem shall notify Xeris, in advance to the extent practical, of any inspections by a Competent Authority specifically related to the Product If
results of an unrelated inspection by a Competent Authority may impact Product. Bachem shall notify Xeris promptly, this includes unrelated inspectional findings that may impact the process, facilities, equipment, laboratories or personnel used to
manufacture, test and store Xeris Products. 
 Interactions with Competent Authorities. In the cases of responses to findings by
inspectors representing Competent Authorities, Bachem will meet mandatory response timelines and m the case where time is needed to provide a complete response. Bachem will notify the Competent Authority and work aggressively to ensure the complete
responses meet timelines specified by the Competent Authorities Bachem will provide Xeris with copies of all correspondence including corrective actions for those observations impacting Xeris products. In the case when DMF queries received by Bachem
from Competent Authorities are associated with third parties’ applications, Bachem will notify Xeris if the regulatory queries may impact Xeris’s Pharmaceutical Products and program timelines. In the case when queries or requested changes
from regulators may produce a conflict between Xeris’s Pharmaceutical Products and program(s) and Bachem’s’ changes relative to a third party’s application. Bachem will reasonably cooperate with Xeris in order to limit impact on
Xeris’s Pharmaceutical Products and programs. Xeris will also cooperate in good faith to support the intended change. 

Section 6.19 Latent Defects. Upon discovery that any batch, previously approved by Bachem and delivered to Xeris, fails to
conform to its Specifications or the regulatory dossier or has in any way been adulterated. Bachem shall promptly notify Xeris of such failure and of the nature thereof in detail, including supplying Xeris with all relevant investigation reports and
data. If Xeris notices any Latent Defects. Xeris shall inform Bachem in writing immediately, but no later than [***] alter their discovery and within [***] after receipt of the respective batch of Product. Xeris shall simultaneously send samples of
the alleged faulty Product to Bachem. Bachem shall investigate all such failures promptly, at its expense, and co-operate with Xeris in determining the cause for the failure and the corrective action required.

 Section 6.20 Product Complaints. Xeris shall be responsible for coordinating The investigation of any complaints about
the Xeris’ Pharmaceutical Product made from Product(s) and shall notify Bachem of any complaint which may be related to The quality of Product Bachem shall investigate and provide a rapid initial response and a report as soon as possible. 

  
 Page 9 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 

Section 6.21 Product Recall. Xeris shall be responsible for instituting a medical product recall scheme for Xeris’
Pharmaceutical Product. Bachem will inform Xeris as soon as possible, but no later than [***] after Bachem becomes aware of such information. In case Xeris does not agree then Xeris releases Bachem from all consequent financial and liability
obligations. Xeris shall notify Bachem of any recall of Xeris’ Pharmaceutical Product, which may be due to manufacture, components or tests performed on Product(s) by Bachem. Bachem shall provide a rapid initial response and then a full report
as soon as possible The Parties shall cooperate on the response to the authorities. 
 ARTICLE 7 

DEVIATIONS AND INVESTIGATIONS 

Section 7.1 Deviations. (Major) Bachem shall ensure that any Major Deviation is carefully investigated, evaluated and
documented by quality assurance of Bachem Investigations shall include root cause determination and corrective actions, where applicable which must be reviewed and approved by Bachem’s quality assurance personnel Bachem will provide access to
alt documentation with respect to Major Deviations to Xeris on-site at Bachem’s facility. 

Section 7.2 Deviations. (Minor) Bachem shall ensure that any Minor Deviation is carefully evaluated and documented by
quality assurance of Bachem. In the case of Minor Deviations Bachem quality assurance and regulatory affairs will evaluate the acceptability regarding GMP, and the impact on conformity with regulatory submissions. Each investigation must give rise
to an explanation and for corrective action, which must be reviewed and approved by Bachem’s quality assurance personnel Bachem will ensure investigation closeout and corrective actions are completed prior to release of Product, if applicable
Bachem will provide access to all documentation with respect to Minor Deviations to Xeris on-site al Bachem’s facility. 

Section 7.3 OOS Results, and Failure Investigations. Bachem shall be responsible for investigating any OOS results that
occur with testing of the Product. According to Bachem’s OOS procedure, an initial tab error investigation will clarify whether the OOS result was caused by a lab error or by a batch failure. In case of a batch failure the Investigation will be
expanded at minimum to evaluate the cause of the failure and its impact on earlier and later production lots. Each investigation must give use to an explanation and/or corrective action which must be reviewed and approved by Bachem’s quality
assurance. OOS and failure investigations must be completed prior to Product release. 
 ARTICLE 8 

CHANGE CONTROL 

Section 8.1 Change Control. Bachem shall maintain a local Change control system that ensures compliance with GMP regulatory
submissions and with all provisions of this Quality Assurance Agreement. All changes will be evaluated by competent management personnel 

  
 Page 10 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 

regarding the technical implications Bachem’s quality assurance and regulatory affairs will evaluate the acceptability of the changes to Product
regarding GMPs, the impact on Product quality end stability as well as on conformity with regulatory submissions. Bachem will notify Xeris of any/all proposed Major Changes to the manufacturing process, quality controls, specifications, methods of
control, prior to initiation. 
 ARTICLE 9 

VALIDATION AND QUALIFICATION 

Section 9.1 Process Validation. Bachem will ensure that the manufacturing process used is fully validated, approved by
Bachem’s Quality Assurance and Regulatory Affairs groups and meets Competent Authorities requirements. Bachem will document the process validation, and at Xeris’ request, disclose such documentation to Xeris for on-site review at Bachem. 
 Section 9.2 Equipment Calibration. Bachem shall be responsible
for ensuring that manufacturing is carried out according to Competent Authorities requirements and ICH Q7 rules using calibrated equipment Bachem shall be solely responsible for the equipment calibration and equipment maintenance program including
record retention, recall bra lion, and preventive maintenance 
 Section 9.3 Cleaning Validation. Bachem shall be responsible
for ensuring that adequate cleaning is carried out between batches of different products to prevent cross contamination Bachem shall also be responsible for conducting cleaning verification or validation as appropriate (to ensure the integrity of
all products, including critical carry-over from similar batches). 
 Section 9.4 Facility and Utility Qualification (IQ, OQ,
PQ). Bachem Shall be responsible for The qualification and maintenance as appropriate of all relevant utilities, equipment, computer systems and facilities associated with the manufacture, storage or testing of Product according to Competent
Authorities requirements. 
 ARTICLE 10 

SPECIFIC RESPONSIBILITIES 

Without limiting each Party’s rights and obligations as otherwise set forth in this Quality Assurance Agreement, the following chart sets
forth each Party’s specific responsibilities in connection with quality assurance matters relating to the manufacture of Product: 
  

					
	 RESPONSIBILITY
	  	Bachem	 	Xeris
	 Manufacture
	  		 	—  
	 Manufacture of the API
	  	[***]	 	[***]
	 Development of manufacturing process for the API
	  	[***]	 	[***]
	 Manufacturing documentation for the API
	  	[***]	 	[***]
	 Ownership of manufacturing process and documentation for the API
	  	[***]	 	[***]

  
 Page 11 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 
  

									
	 RESPONSIBILITY
	  	Bachem	 	 	Xeris	 
			
	 Procurement of the API raw and starting materials
	  	 	[***]	 	 	 	[***]	 
			
	 Analytical, Laboratory, Sampling and Control
	  				 			
			
	 Retain and store samples of all materials and the API
	  	 	[***]	 	 	 	[***]	 
			
	 Sampling, analysis and release of materials for API
	  	 	[***]	 	 	 	[***]	 
			
	 In-process analyses for manufacture of the API
	  	 	[***]	 	 	 	[***]	 
			
	 Reference standards for laboratory analysis performed by Bachem
	  	 	[***]	 	 	 	[***]	 
			
	 Incoming material testing of the API upon receipt and keeping retained samples as required by
competent authorities
	  	 	[***]	 	 	 	[***]	 
			
	 Quality Assurance Activities for API
	  				 			
			
	 Batch numbering _
	  	 	[***]	 	 	 	[***]	 
			
	 Approval of master batch documents
	  	 	[***]	 	 	 	[***]	 
			
	 Preparation and review of the batch production, analytical and packaging records as well as of
associated documents
	  	 	[***]	 	 	 	[***]	 
			
	 Assurance of correct storage conditions for the API prior to shipment to Xeris
	  	 	[***]	 	 	 	[***]	 
			
	 Release of API to Xeris
	  	 	[***]	 	 	 	[***]	 
			
	 Release of API for Xeris’ Pharmaceutical Product manufacture
	  	 	[***]	 	 	 	[***]	 
			
	 Shipping documentation
	  	 	[***]	 	 	 	[***]	 
			
	 Material safety data sheet provision
	  	 	[***]	 	 	 	[***]	 
			
	 Maintain a change control system
	  	 	[***]	 	 	 	[***]	 
			
	 Provide API Specification as maintained in DMF
	  	 	[***]	 	 	 	[***]	 
			
	 Approve API Specifications and ensure that Specifications are appropriate for further use
	  	 	[***]	 	 	 	[***]	 
			
	 Change Control for Specifications (Bachem for technical feasibility, Xeris for further
use)
	  	 	[***]	 	 	 	[***]	 
			
	 Failure investigation in case of batch failure
	  	 	[***]	 	 	 	[***]	 
			
	 Regulatory Documentation for API
	  				 			
			
	 Scheduling and ordering the regulatory work documentation and submissions for API section of
Xeris’ Drug Products, as needed
	  	 	[***]	 	 	 	[***]	 
			
	 Submission and maintenance of DMF for API
	  	 	[***]	 	 			
			
	 Stability studies for The API
	  	 	[***]	 	 	 	[***]	 
			
	 NDA or MAA submission and maintenance (or Xeris1 Drug Products
	  	 	[***]	 	 	 	[***]	 
			
	 Hosting GMP Inspections for the API by the Competent Authorities
	  	 	[***]	 	 	 	[***]	 
			
	 Maintain site registration licenses
	  	 	[***]	 	 	 	[***]	 
			
	 Validation for API
	  				 			
			
	 Qualification of equipment for manufacturing and analysis
	  	 	[***]	 	 	 	[***]	 

  
 Page 12 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 
  

									
	 RESPONSIBILITY
	  	Bachem	 	 	Xeris	 
			
	 Cleaning validation and cleaning verification
	  	 	[***]	 	 	 	[***]	 
			
	 Validation of test methods
	  	 	[***]	 	 	 	[***]	 
			
	 validation of manufacturing process
	  	 	[***]	 	 	 	[***]	 
			
	 Validation of computerized systems
	  	 	[***]	 	 	 	[***]	 
			
	 Complaint Handling, Drug Safety
	  				 			
			
	 Review and resolution of Xeris’ Pharmaceutical Product quality complaints when applicable to
API
	  	 	[***]	 	 	 	[***]	 
			
	 Decisions regarding the notification of critical API quality issues to Swissmedic and
Xeris
	  	 	[***]	 	 	 	[***]	 
			
	 Decisions regarding recalls and field alerts of Xeris’ Pharmaceutical Product
	  	 	[***]	 	 	 	[***]	 

 ARTICLE 11 

CONFIDENTIALITY 

Section 11.1 Confidentiality Restriction of Use. The Confidential Information communicated by one Party to The other Party
under this Quality Assurance Agreement through written documents or by any other means or any pan thereof shall be kept in confidence by the receiving Party which agrees to use the Confidential Information solely for The purpose of implementing this
Quality Assurance Agreement. This confidentiality shall survive the termination of this Quality Assurance Agreement for [***] years 

ARTICLE 12 

MISCELLANEOUS 

Section 12.1 Review terms of QAA. Bachem and Xeris shall evaluate in good faith the validity of the provisions defined in this
Quality Assurance Agreement every [***] years (or sooner, to the extent required by applicable laws of the manufacturing site) starting at the Effective Date. 

Section 12.2 Governing Law, Dispute Resolution. Any dispute a using cut of or in connection with this Quality Assurance Agreement,
including any question regarding its existence, validity or termination, shall be referred lo and finally resolved by arbitration under the London Court of International Arbitration Rules, which Rules are deemed to be incorporated herein by
reference. The number of arbitrators shall be one. The seal, or legal place, of arbitration shall be London, England. The language to be used in the arbitral proceedings shall be English. The governing law of the contract shall be the substantive
law of Switzerland. 
 Section 12.3 Annexes. The Annexes referenced in this Quality Assurance Agreement are specifically made a
part hereto. 
 Section 12.4 Amendment. Any amendment or modification of this Quality Assurance Agreement must be in writing and
signed by authorized representatives of both Parties. 

  
 Page 13 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 

Section 12.5 Prevailing Agreement. To the extent that there is a conflict between, or ambiguity relating to this Quality Assurance
Agreement and any other Agreement, the wording of this Quality Assurance Agreement shall govern any and all quality matters. 

Section 12.6 Language. This Quality Assurance Agreement is made in the English language. 

Section 12.7 Number of Copies. Two master copies exist, one with each of the Parties. 

Section 12.8 Term. This Quality Assurance Agreement shall commence as of the Effective Date and shall terminate [***] years after
shipment of the final Batch of Product. For clarity, this Quality Assurance Agreement shall be terminated automatically, if no shipments of the Product to Xeris have been made over a period of [***] consecutive years. Termination of this Quality
Assurance Agreement shall not relieve the Parties of any obligation accruing prior lo termination and shall not extinguish any antecedent breach of any provisions thereof, and such provisions of this Quality Assurance Agreement which, by their
terms, survive shall continue in full force and effect after such termination. 
 Section 12.9 Assignment. Neither of the
Parties shall assign or transfer this Quality Assurance Agreement or any of their respective rights or obligations hereunder without the prior written consent of the other Party, which shall not be unreasonably withheld or delayed, except that
either Party may assign this Agreement and The rights and obligations hereunder without the consent of the other Party to any person succeeding to all or substantially all of the business or assets of The Party relating to the Product 

  
 Page 14 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 

IN WITNESS WHEREOF, the Parties have caused this Quality Assurance Agreement lo be duly executed by their authorized representatives on
the Effective Dale. 
 Bubendorf .Switzerland 
  

							
		 	 Bachem AG
	 		 	
				
	 By
	 	 /s/ Gerard Haas December 9, 2015
	 	By:	 	 /s/ Jan van Bebber December 9, 2015

		 	 Dr Gerhard Haas
	 		 	 Dr. Jan van Bebber

		 	 VP QAVRA
	 		 	 Director QA/RA

 Austin. TX USA 
  

			
	 Xeris Inc.

		
	 By
	 	 /s/ Yash Sabharwal November 20, 2015

		 	 Yash Sabharwal

		 	 Chief Operating Officer

		
	 By
	 	 /s/ Banir Ruano November 20, 2015

		 	 Banir Ruano

		 	 VP of Global Manufacturing & Tech Ops

		
	 By
	 	 /s/ Rebecca Waterbury December 2, 2015

		 	Rebecca Waterbury
		 	 VP of Quality

  
 Page 15 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 
  

					
	Xeris / Bachem Quality Assurance Agreement	  	 ANNEX 1
  

SPECIFICATIONS
	  	Glucagon

 The Product shall be released against the following Specifications: 

  
 Page 16 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 

Product: Glucagon, Pharma Grade Material 
 [***] 

[***] 

  
 Page 17 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED 
  

 CONFIDENTIAL 
  

					
	Xeris / Bachem Quality Assurance Agreement	  	 ANNEX 2
  

APPROVED CONTRACT LABORATORIES
	  	Glucagon

 Certain analytical services are provided (or Bachem AG by contract laboratories. Following please find the list of these
institutes / companies including their potential service(s). All listed subcontractors are appropriately Qualified by Bachem Alternatively to using a contract laboratory these tests may be performed in house at Bachem provided that the specific
technique is available. 
  

			
	 Contract laboratory
	  	 Description of typical service(s)

	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	

  
 Page 18 of 18 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL
SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 

Amendment 1 to the 

Quality Assurance Agreement 
 This
Amendment 1 (the “Amendment 1”) is made as of October 31, 2016 (the “Effective Date”) by and between Bachem AG, an entity organized under the laws of Switzerland, with its principal place of business at
Hauptstrasse 144, CH-4416 Bubendorf, Switzerland (“Bachem”), and Xeris Pharmaceuticals, Inc., an entity organized under the laws of Texas, with its principal place of business at 3208 Red
River Street, Suite 300, Austin, TX 78705, USA (“Xeris”). 
 PREAMBLE 

WHEREAS, Bachem and Xeris have entered into a Quality Assurance Agreement between the Parties effective as of November 20, 2015
the “Quality Assurance Agreement”; 
 WHEREAS, Bachem and Xeris now mutually desire to amend, modify and restate certain
terms and conditions of the Quality Assurance Agreement. 
 NOW THEREFORE, the Parties hereto, intending to be legally bound, agree
as follows: 
  

	 	1.	Definitions 

 The capitalized terms used in this Amendment 1 shall have the meaning ascribed to
such terms in the Quality Assurance Agreement, unless otherwise stated. 
  

	 	2.	Amendments 

 The Parties agree that, as of the Effective Date, the Quality Assurance Agreement is
amended as set forth in this Section 2. 
 2.1 Section 3.3 (Notices to Xeris) of the Quality Assurance Agreement
shall be deleted in its entirety and replaced by the following: 
 Section 3.3 Notices to Xeris. Any notice to Xeris shall be addressed
to: 
 Xeris Pharmaceuticals, Inc., 3208 Red River Street, Suite 300 

Austin, TX 78705 
 [***] 

 

	 	3.	MISCELLANEOUS 

 3.1 The Parties agree that the provisions of this Amendment 1 shall be
applied with immediate effect. For the avoidance of doubt it is acknowledged that the provisions of this Amendment 1 shall be valid for future manufacturing and release of the Product. 

3.2 In the event of any conflict between the terms of this Amendment 1 and the terms of the Quality Assurance Agreement the terms of this
Amendment 1 shall prevail. 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL
SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED 
  

 3.3 Except as expressly modified by this Amendment 1, the terms and provisions of the Quality
Assurance Agreement remain and shall remain in full force and effect. 
 IN WITNESS WHEREOF, the Parties have caused this Amendment 1
to the Quality Assurance Agreement to be duly executed by their authorized representatives on the Effective Date. 

Bubendorf, November 3, 2016 

Bachem AG 
  

							
	By:	 	 /s/ Gerard Haas
	 	By:	 	 /s/ Jan van Bebber

		 	Dr. Gerhard Haas	 		 	Dr. Jan van Bebber
		 	Vice President QA/RA	 		 	Director QA/RA

 Austin, TX USA, November 7, 2016 

Xeris Inc. 
  

			
	By:	 	 /s/ Benir Ruano

		 	Benir Ruano
		 	VP of Global Manufacturing & Tech Ops

  

			
	By:	 	 /s/ Leslie Osmera

		 	Leslie Osmera
		 	VP of QA

  
 2 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL
SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED 
  

 Amendment 2 to the 

Quality Assurance Agreement 

This Amendment 2 (the “Amendment 2”) is made as of January 26, 2017 (the “Effective
Date”) by and between Bachem AG, an entity organized under the laws of Switzerland, with its principal place of business at Hauptstrasse 144, CH-4416 Bubendorf, Switzerland
(“Bachem”), and Xeris Pharmaceuticals, Inc., an entity organized under the laws of Texas, with its principal place of business at 3208 Red River Street, Suite 300, Austin, TX 78705, USA (“Xeris”). 

PREAMBLE 
 WHEREAS,
Bachem and Xeris have entered into a Quality Assurance Agreement between the Parties effective as of November 20, 2015, an amendment to the Quality Assurance Agreement dated October 31, 2016 (“Amendment 1”) collectively
comprising the “Quality Assurance Agreement”; 
 WHEREAS, Bachem and Xeris now mutually desire to amend, modify and
restate certain terms and conditions of the Quality Assurance Agreement. 
 NOW THEREFORE, the Parties hereto, intending to be
legally bound, agree as follows: 
  

	 	1.	DEFINITIONS 

 The capitalized terms used in this Amendment 2 shall have the meaning
ascribed to such terms in the Quality Assurance Agreement, unless otherwise stated. 
  

	 	2.	AMENDMENTS 

 The Parties agree that, as of the Effective Date, the Quality Assurance
Agreement is amended as set forth in this Section 2. 
 2.1 Exhibit A (Specifications) of the Quality Assurance Agreement shall be
deleted in its entirety and replaced by the following: 
 (The remainder of this page is intentionally left blank) 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL
SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED 
  

					
	 Xeris / Bachem Quality
 Assurance
Agreement
	  	 ANNEX 1
  

SPECIFICATIONS
	 	Glucagon

 The Product shall be released against the following Specifications: 

[***] 
  

					
	 Tests
	 	 Specifications
	  	 Controls

	Appearance R	 	[***]	  	
	Appearance of solution R 	 	[***]	  	
	Identification (HPLC)	 	[***]	  	
	Identification (HPLC)1,2	 	[***]	  	
	Identification (amino acid analysis)	 	 [***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
[***]
	  	
	Identification (MS)2	 	[***]	  	
	Specific optical rotation	 	[***]	  	
			
	Related substances (HPLC) R	 	[***]	  	
			
	Peptide content R
(elemental analysis)	 	[***]	  	
	Assay (HPLC) 1,2,R	 	[***]	  	
	Bioassay	 	[***]	  	
	Mass balance	 	[***]	  	
	Water content (Karl Fischer)R	 	[***]	  	
	Residue on ignition	 	[***]	  	
	Acetic acid content (HPLC)	 	[***]	  	
	Ammonium content (IC)	 	[***]	  	
	Chloride content (titration)	 	[***]	  	
	Residual organic solvents (GC)	 	[***]	  	

  
 2 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL
SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

					
		 	 [***]
	 	
			
	Nitrogen content R (elemental analysis)	 	[***]	 	
			
	Zinc content (ICP-OES)	 	[***]	 	
			
	Bacterial endotoxins (USP <85>)	 	[***]	 	
			
	Microbial limit test (USP <61>) Total aerobic microbial count (TAMC)	 	[***]	 	
			
	Total yeasts and moulds count (TYMC)	 	[***]	 	

  

	R 	performed for retest 

	1 	the analytical test method is based on the Glucagon monograph of [***] 

	2 	report separately as Additional Data 

 To be analyzed according to [***] 

Product: Glucagon, Pharma Grade Material 
 Bachem No.: [***]

 Peptide Sequence: [***] 
  

	 	3.	MISCELLANEOUS 

 3.1 The Parties agree that the provisions of this Amendment 2 shall be
applied with immediate effect. For the avoidance of doubt it is acknowledged that the provisions of this Amendment 2 shall be valid for future manufacturing and release of the Product. 

3.2 Both Parties acknowledge and Xeris agrees that there will be a Major Change to the existing Quality Assurance Agreement within the next
months (Change request letter dated February 22, 2016) and therefore the Agreement will be amended with the new Quality Standard reflecting such Change as soon as available. 

3.3 In the event of any conflict between the terms of this Amendment 2 and the terms of the Quality Assurance Agreement or the terms of the
Amendment 1, the terms of this Amendment 2 shall prevail. 
 3.4 Except as expressly modified by this Amendment 2, the terms and provisions
of the Quality Assurance Agreement and Amendment 1 remain and shall remain in full force and effect. 
 IN WITNESS WHEREOF, the Parties have
caused this Amendment 2 to the Quality Assurance Agreement to be duly executed by their authorized representatives on the Effective Date. 

  
 3 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL
SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 
 COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED 
  

 Bubendorf, February 8, 2017 

Bachem AG 
  

					
	 By:
	 	 /s/ Gerard Haas
	  	 /s/ Jan van Bebber

	Dr.	 	Gerhard Haas	  	Dr. Jan van Bebber
	 Vice President QA/RA
	  	Director QA/RA
		
	 Austin, TX USA, February 16, 2017
	  	
	 Xeris Inc.
	  	
			
	By:	 	 /s/ Benir Ruano
	  	 /s/ Leslie Osmera

	 Benir Ruano
	  	Leslie Osmera
	 VP of Global Manufacturing & Tech Ops
	  	VP of QA

  
 4EX-10.14

 Exhibit 10.14 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 1
 of 27

  
  

Commercial Supply Agreement 
 This
Commercial Supply Agreement (“Agreement”) is made and entered into as of May 14, 2018 (“Effective Date”) by and between PYRAMID Laboratories Inc. (“PYRAMID”), a California Corporation, having its principal place of
business at 3598 Cadillac Avenue, Costa Mesa, California 92626 and Xeris Pharmaceuticals, Inc. (“Client”), a Delaware corporation, having its principal place of business at 180 N. LaSalle Street, Suite 1800, Chicago, Illinois, 60601,
collectively the “Parties” and individually a “Party”. 
 PURPOSE 

Client is engaged in the research, development and commercialization of pharmaceutical products; 

PYRAMID is engaged in the business of providing product development and commercial manufacturing services for pharmaceutical products; 

PYRAMID and Client previously entered into a Master Service Agreement on November 1, 2016 (“Master Service Agreement”) to provide development
services, produce clinical supplies, and produce commercial registration batches for pharmaceutical development programs, including products now defined as Commercial Product; 

NOW, THEREFORE, Client wishes to engage PYRAMID to perform the cGMP manufacturing Services for Commercial Product and PYRAMID wishes to provide such
manufacturing Services to Client, all in accordance with the terms and conditions of this Agreement; 
 NOW, THEREFORE, in consideration of the mutual
covenants and premises herein contained, the Parties hereto agree as follows: 
 AGREEMENT 

 

	1.	DEFINITIONS  

  

	 	1.1	“Active Pharmaceutical Ingredient”(“API”) means Glucagon Pharmaceutical Grade material as supplied by Client. 

 

	 	1.2	“Affiliates” means any corporation, firm, partnership or other entity which directly or indirectly controls, is controlled by, or is under common control of a Party to this Agreement. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 2
 of 27

  

	 	1.3	“Client Materials” means any Active Pharmaceutical Ingredients, equipment, or primary container components supplied to PYRAMID by Client for testing or manufacture of Commercial Product under any Firm
Order or Purchase Order. Client Materials are listed in Schedule B. 

  

	 	1.4	“Commercial Product” means the products listed in Schedule C. 

  

	 	1.5	“Firm Order” has the meaning specified Section 3.2. 

  

	 	1.6	“FDA” means the United States Food and Drug Administration. 

  

	 	1.7	“cGMP” means the current Good Manufacturing Practices for manufacturing finished pharmaceutical products as set forth in 21 CFR Parts 210 and 211, the guidelines to GMP (under European directive
2003/94/EC) or any foreign equivalent specified in the applicable Firm Order or Purchase Order. 

  

	 	1.8	“Batch”means a specific quantity of manufactured Commercial Product, or a specific identified portion thereof (each a specific batch or sub-lot), having uniform characteristics and quality within limits
as defined in the Specifications (and as set forth in 21 CFR Part 211). 

  

	 	1.9	“Purchase Order” means an order for Commercial Product pursuant to the terms of this Agreement and the Quality Agreement, and as defined in Section 3.2. 

 

	 	1.10	“Quality Agreement” means the Quality Agreement between the Parties dated November 16, 2016, and as may be further amended from time to time, which contains current Commercial Product
Specifications and specifies Parties’ respective responsibilities regarding the manufacture, packaging, testing, storage, release, quality control, quality assurance and shipment of Commercial Product in accordance with requirements of
Regulatory Standards and cGMP’s. In the event that any conflict shall arise between the terms of this Agreement and the Quality Agreement, the terms of this Agreement shall take precedence over the terms of the Quality Agreement in all respects
except matters of quality, regulatory affairs and pharmacovigilance, in which case the Quality Agreement shall take precedence. 

  

	 	1.11	“Regulatory Standards” means requirements of the FDA or any foreign equivalent requirements for PYRAMID’s facility, cGMP and all other regulations applicable to PYRAMID, PYRAMID’s facility,
and PYRAMID’s manufacture, packaging, testing, quality control, quality assurance and shipment of Commercial Product. 

  

	 	1.12	“Services” has the meaning defined in Section 2. 

  

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 3
 of 27

  

	 	1.13	“Specifications” means: 

  

	 	(a)	the file, for the Commercial Product, which is provided by Client to PYRAMID and which contains documents related to such Commercial Product, including, without limitation: 

(1) written Specifications for Active Pharmaceutical Ingredient, primary container components, PYRAMID supplied materials and consumables, and
finished Commercial Product; 
 (2) manufacturing, process control, packaging and labeling Specifications; 

(3) shipping and storage requirements; 

(4) all environmental, health and safety information relating to Client Materials and Commercial Product including materials safety data
sheets, all as updated, amended and revised from time to time by Client in accordance with the terms of the Agreement; and 
 (5) any other
technical information necessary to carry out the contracted operations correctly in accordance with any legal requirements. 
  

	 	1.15	“Contract Year” means the twelve (12) month period commencing, in the case of the first year of this Agreement, on the Effective Date, and thereafter commencing on the twelve (12) month
anniversary date in subsequent years. 

  

	 	1.16	“Calendar Year” means in the case of the first year of this Agreement, the Effective Date through December 31st of the same year, and thereafter
January 1 through December 31st in subsequent years. 

  

	 	1.17	“Validation Batch” means a Batch that requires testing and documentation beyond what is required per this Agreement. 

 

	 	1.18	“Intellectual Property” means any and all of the following in any jurisdiction throughout the world: (i) trademarks, trade dress, trade names and service marks, including all applications and
registrations therefor and the goodwill connected with the use of and symbolized by the foregoing; (ii) works of authorship and copyrights, including all applications and registrations related to the foregoing; (iii) trade secrets,
proprietary information, inventions and confidential know-how; (iv) patents and patent applications; (v) internet domain name registrations, social media and other identifiers of source; and (vi) other intellectual property and
related proprietary rights, interests and protections. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 4
 of 27

  

	2.	SCOPE OF AGREEMENT 

 Under this Agreement, Client may request PYRAMID to manufacture,
fill, package, label, store, and test Commercial Product from time to time (“Services”). PYRAMID shall: 
  

	 	2.1	Ensure that all manufacturing under this Agreement shall be in accordance with the Specifications, the Quality Agreement, Regulatory Standards, cGMP’s and a Purchase Order. 

 

	 	2.2	PYRAMID shall perform quality control and quality assurance testing in accordance with the protocols specified in the Specifications and Quality Agreement. PYRAMID shall not make any changes to such testing protocols
without the prior written approval from Client. In the event that any Batch of Commercial Product fails test Specifications, PYRAMID and Client, in accordance with the Quality Agreement, shall jointly determine the proceedings and methods to be
undertaken to investigate the causes of such failure, including which Party shall bear the cost of such investigation, provided that PYRAMID shall not be liable for any such costs unless there has been a failure by PYRAMID to provide the Services in
accordance with this Agreement or the Quality Agreement. PYRAMID will provide any and all data and results relating to the testing upon request by Client. 

  

	 	2.3	PYRAMID shall receive and perform identity testing of all materials, including PYRAMID supplies, materials and consumables and Client Materials, including the Active Pharmaceutical Ingredient, necessary for
manufacturing or as otherwise specified in the Quality Agreement and as necessary to meet cGMP requirements. 

  

	 	2.4	Client shall supply all of the items listed in Schedule B to PYRAMID and Client shall be solely responsible for all costs and expenses relating thereto. Client shall be responsible for ensuring that Client Materials
listed in Schedule B are ordered in sufficient quantities and delivered to PYRAMID in sufficient time to enable PYRAMID to meet Rolling Forecast and Firm Order requirements of Client. Client Materials, including the Active Pharmaceutical Ingredient,
shall at all times belong to and remain the property of Client. PYRAMID agrees that Client Materials received by PYRAMID shall only be used to provide Services for the Client. Any excess Client Materials shall be returned to Client or destroyed, at
Client’s expense, upon request and/or upon expiration or termination of this Agreement. 

  

	3.	ORDERING 

  

	 	3.1	Forecasts 

  

	 	3.1.1.	 Prior to the end of each month, beginning approximately [***] prior to the expected FDA approval date for a
Commercial Product, Client shall 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 5
 of 27

  

	 	
provide a written [***] forecast of the volume for each Commercial Product that Client anticipates will be required to be produced and delivered to Client (or designee) during the following [***]
(“Rolling Forecast”). Rolling Forecasts will be updated by Client at the end of each subsequent month and PYRAMID shall inform Client within [***] of receiving an updated forecast if a Rolling Forecast cannot be met or is at risk of not
being met. Failure of PYRAMID to accept or reject a Rolling Forecast within [***] of receipt shall be deemed an acceptance of the forecast and confirmation of having suitable available capacity for [***] of the Rolling Forecast. 

 

	 	3.1.2.	At the beginning of each Calendar Year, Client shall provide a written [***] forecast for each Commercial Product (“Long Term Forecast”). PYRAMID shall review the Long-Term Forecast within [***] and provide a
written commitment of total production capacity available for Commercial Product for the following [***] period (“Total Capacity Commitment”). Failure of PYRAMID to accept or reject a Long-Term Forecast within [***] of receipt shall be
deemed as making a Total Capacity Commitment for [***] of the Long-Term Forecast. If Client’s Long-Term Forecast cannot be manufactured due to PYRAMID’s limitations of the Total Capacity Commitment, Parties agree in good faith to evaluate
and agree to alternative solutions, provided however, Client shall have the option of [***] as provided for under Section 24. 

  

	 	3.2	Orders 

  

	 	3.2.1	On or before the last day of each month, Client shall provide firm written orders for Commercial Product to PYRAMID, and such orders shall specify the amount of Commercial Product that shall be produced by PYRAMID and
delivered to Client on a date not less than [***] from the first day of the following month (each a “Firm Order”). Firm Orders shall be submitted to PYRAMID in the form of individual or multiple Purchase Orders and shall specify
Client’s Purchase Order number, quantities for each Commercial Product, delivery schedule, and any other elements necessary to ensure the timely production and delivery of the Commercial Product (each a “Purchase Order”). Purchase
Orders for Commercial Products shall be firm and binding on Client except as otherwise provided for in Sections 3.2.4 and 3.2.5. 

  

	 	3.2.2	Each batch of Commercial Product shall have an expected output based on manufacturing scale and yield (“Target Batch Yield”), as further defined in Schedule A, and may only submit Purchase Orders for
Commercial Product in multiples of the Target Batch Yield. At the beginning of each Calendar Year, Parties agree to review and revise Target Batch Yield for Commercial Products, as necessary, based on updated production history. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 6
 of 27

  

	 	3.2.3	PYRAMID shall inform Client within [***] in writing or by email if a Purchase Order cannot be filled and delivered as requested. Failure of PYRAMID to accept or reject a Purchase Order within [***] of receipt shall be
deemed an acceptance of the Purchase Order. 

  

	 	3.2.4	[***]. 

  

	 	3.2.5	Client shall not be allowed to adjust or cancel a Purchase Order [***] unless Parties mutually agree to utilize manufacturing time allocated for the Purchase Order for another Commercial Product or comparable Client
special project under the Master Service Agreement. 

  

	 	3.2.6	Client Materials must be received by PYRAMID at least [***] in advance of scheduled Purchase Order manufacturing in order to reserve necessary PYRAMID resources and manufacturing time. 

 

	 	3.2.7	Each Batch under a Purchase Order delivered more than [***] beyond the delivery date specified in a Purchase Order shall be considered a Late Delivery (“Late Delivery”) and PYRAMID shall incur a penalty as
further defined in Section 7.2. For clarity, Late Deliveries due to (a) Client’s failure to supply Client Materials in advance of scheduled manufacturing, or (b) quality issues related to such Client Materials, or
(c) changes agreed upon in Sections 3.2.4 and 3.2.5 shall not be considered a Late Delivery. 

  

	 	3.3	Pricing 

  

	 	3.3.1	At the beginning of each Calendar Year, based on the quantity of Commercial Product forecasted by Client in the most recent Rolling Forecast for that Calendar Year, Parties agree to select and apply the appropriate
pricing schedule as defined in Schedule A. The selected pricing schedule shall apply to all Client’s Purchase Orders scheduled for delivery during that Calendar Year, including Purchase Orders previously created and scheduled for delivery in
that Calendar Year, and for which pricing shall be adjusted accordingly as required. 

  

	 	3.3.2	Parties agree that prices set forth in Schedule A shall be updated [***]. 

  

	 	3.3.3	Parties agree that since Validation Batches require additional documentation and testing, pricing for any such Validation Batches shall be [***] compared to the then applicable Commercial Product Purchase Order price.
PYRAMID will produce a Validation Batch only upon the written request of Client submitted in a Purchase Order. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 7
 of 27

  

	 	3.3.4	At the end of each Calendar Year, based on the actual quantity of Commercial Product ordered by Client, defined as all Purchase Orders scheduled for delivery in that Calendar Year, Parties agree to review annual
purchase volume to determine if a different pricing schedule should have been applied for the past full Calendar Year. As a result of the review and reconciliation process, and if required, PYRAMID shall issue a credit to Client for any amount due
and apply it to the following years purchases, or Client shall pay PYRAMID for any amount due [***] of completing the year end reconciliation process. 

  

	4.	MANUFACTURING 

  

	 	4.1	PYRAMID will manufacture, package and label Batches for Purchase Orders in accordance with Section 2 of this Agreement, Commercial Product Specifications, the Quality Agreement and cGMP’s. 

 

	 	4.2	PYRAMID shall test Batches and deliver Batch documentation for each Purchase Order to Client in accordance with the Quality Agreement, and such Batch documentation shall be delivered to Client at least [***] prior to
the delivery date specified on each Purchase Order. 

  

	 	4.3	If the yield of a Batch is [***] below the Target Batch Yield as defined in Schedule A, Parties agree to investigate the root cause for the lower yield in accordance with the Quality Agreement. If the cause of the lower
than expected yield is due to operator error or gross negligence by PYRAMID, PYRAMID may be subject to a penalty as further defined in Section 7.2. 

  

	 	4.4	PYRAMID shall replace any Batch that does not meet Specifications and is due to PYRAMID failure [***] and as soon as reasonably possible, and PYRAMID shall [***] as defined in Section 7.2.5. For clarity, any Batch
rejection due to a failure of Client Materials shall not result in a PYRAMID liability as provided for herein and Parties shall work together at Client’s cost to replace the Batch as soon as reasonably possible. 

 

	 	4.5	Services related to Commercial Product that are outside of routine commercial manufacturing and supply as defined within this Agreement shall be managed separately as special projects and in accordance with the Master
Service Agreement. 

  

	5.	SPECIFICATIONS 

 Specifications for Commercial Product and any proposed revision to such
Specifications shall be managed in accordance with the Quality Agreement. Revisions to Specifications requested by either Party will only be implemented following a technical review and cost 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 8
 of 27

  

 
assessment by PYRAMID and are subject to Client and PYRAMID reaching agreement as to pricing revisions in Schedule A, if necessitated by any such revision. If Client accepts a proposed price
change, the proposed revision to the Specifications shall be implemented in accordance with the Quality Agreement, and the price change shall become effective only with respect to those Purchase Orders that are manufactured in accordance with the
revised Specifications. If Parties cannot agree on a proposed price revision, Client shall have the right to terminate the Agreement in accordance with Section 24. 
  

	6.	SHIPPING 

  

	 	6.1	PYRAMID will prepare and ship Quality Control samples for Commercial Product to a laboratory designated by Client for testing, as required, in accordance with the Specifications and Quality Agreement. 

 

	 	6.2	Once a Commercial Product Batch is fully tested and released in accordance with Sections 4.2 and 9, the Specifications and the Quality Agreement, Client will arrange for pick up and shipment of the Commercial Product in
accordance with the Specifications and Purchase Order. Client shall be responsible for payment of freight, insurance, customs duties and related charges for delivery of packaged Commercial Product to Client or alternate recipient as designated by
Client, unless otherwise specified in the Purchase Order. 

  

	7.	INVOICING, PAYMENT, ADJUSTMENTS 

  

	 	7.1	Invoicing and Payment 

  

	 	7.1.1	

  

	 	7.1.1	Purchase Orders may require a down payment as defined in Schedule A. PYRAMID shall invoice Client for any such down payment upon receipt of a signed Purchase Order and payment of such invoice are due [***] after receipt
by Client. 

  

	 	7.1.2	PYRAMID shall invoice Client for a Purchase Order after Batch documentation, including a Certificate of Analysis with successful sterility and endotoxin test results, has been delivered to Client in accordance with the
Quality Agreement. Each invoice shall identify the Purchase Order number, Client part number, Commercial Product name, quantity delivered, unit price, freight charges and the total amount to be paid by Client. Undisputed invoices are due within
[***] after receipt by Client. 

  

	 	7.1.3	Client agrees to pay PYRAMID for production costs associated with cancelled Firm Orders. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 9
 of 27

  

	 	7.1.4	All late payments shall bear interest at a rate of [***], if not prohibited by law, otherwise at the highest lawful contract rate. 

  

	 	7.1.5	Except as otherwise provided in the applicable Purchase Order, Client will pay to PYRAMID any federal, state and local sales taxes, if applicable, based on or measured by the sale or use of packaged Products, exclusive
of any taxes based on PYRAMID’s income, revenues, gross receipts, personnel, or real or personal property, or other assets. 

  

	 	7.2	Invoice Adjustments 

  

	 	7.2.1	For any firm Purchase Order revised by Client [***] unless Parties mutually agreed to utilize manufacturing time scheduled for the Purchase Order for another purpose, as further defined under Section 3.2.5.

  

	 	7.2.2	For any Batch that is cancelled by Client, and that is associated with a firm Purchase Order, Client shall pay PYRAMID [***] and Client shall have no further obligations for the Purchase Order. 

 

	 	7.2.3	For any Late Delivery of a Batch under a Purchase Order as further defined in Section 3.2.7, PYRAMID shall incur a penalty of [***]. 

 

	 	7.2.4	For any Batch manufactured with a yield of [***] due to PYRAMID operator error or gross negligence as further defined in Section 4.3, Client shall have the option [***] subject to limitations defined under
Section 22. 

  

	 	7.2.5	PYRAMID shall be responsible for the replacement cost of any Batch that does not meet Specifications and is not delivered to Client as further described in Section 4.4, [***] subject to limitations defined under
Section 22. 

  

	 	7.3	Defaults in Payment 

 In the event of default in the payment for Services rendered or
expenses incurred by PYRAMID for Client, pursuant to this Agreement, Client shall be responsible for all collection fees and expenses incurred by PYRAMID, including attorneys’ fees. In the event of default in the reimbursement for Service fees
or Client Materials to Client by PYRAMID, pursuant to this Agreement, PYRAMID shall be responsible for all collection fees and expenses incurred by Client, including attorneys’ fees. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 10
 of 27

  

	8.	CLIENT MATERIALS AND PRODUCT 

  

	 	8.1	Client Materials will remain Client’s property at all times and will only be used by PYRAMID for the purposes of manufacturing Commercial Product in accordance with this Agreement. 

 

	 	8.2	PYRAMID must store and maintain Client Materials in such a way that they are clearly identifiable as Client’s property and in accordance with the Quality Agreement and cGMP. 

 

	 	8.3	Client Materials will be insured by Client against any damages that may occur during the storage at the premises of PYRAMID. PYRAMID will not be liable for destruction or deterioration of these materials unless
destruction or deterioration is due to the negligence or willful misconduct on the part of PYRAMID, and in such case of negligence or willful misconduct, PYRAMID will be insured to cover property loss and limits as further described in
Section 21 and 22. 

  

	 	8.4	Client shall provide to PYRAMID the most current technical data relating to the Commercial Product and Client Materials, including, but not limited to, Specifications, material data safety sheets, and pertinent
environmental health and safety information, necessary to assure safe handling and disposal of the Commercial Product and the Client Materials by PYRAMID employees. 

 

	 	8.5	PYRAMID will provide to Client a monthly inventory report within [***] after the end of each month. The report will include Client Materials, in process Commercial Product, and finished Commercial Product stored or
pending release and shipment, and shall include part number, material description, quantity, lot number, expiration date and material disposition. Parties agree to use best efforts to investigate and reconcile any discrepancies within [***] of
Client receiving such inventory report. 

  

	9	QUALITY ASSURANCE 

 The Quality Agreement, as defined in Section 1, forms an
integrated part of this Agreement and describes in detail cGMP, quality control and quality assurance responsibilities of each Party. The Quality Agreement includes, but is not limited to, technical and quality contact information, roles and
responsibilities, facility and equipment requirements, Commercial Product Specifications, material and vendor management, manufacturing qualification and validation, in-process testing and control, rework or reprocessing, packaging and labeling,
analytical testing methods, Batch disposition and documentation, and storage and transportation. The Quality Agreement shall also address the use of subcontractors, specific regulatory and country reporting requirements, change control, deviation
and nonconforming product investigations, corrective and preventative actions, and dispute resolution. In the event that any conflict shall arise between the terms of this Agreement and the Quality Agreement, the terms of the Quality Agreement shall
take precedence over the terms of this Agreement in all respects related to quality, regulatory affairs and 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 11
 of 27

  

 
pharmacovigilance. Parties agree to review the Quality Agreement within [***] of the Execution Date, and update the Quality Agreement as necessary, to reflect this Agreement and related
requirements. 
  

	10.	REGULATORY INSPECTIONS 

 PYRAMID’s obligations to notify and cooperate with Client
regarding any audit or inspection by a competent regulatory authority with respect to the manufacture or testing of Products will be as set out in the Quality Agreement. All costs associated with PYRAMID’s compliance or support with
(a) any official requests for information or documents relating to Services performed or Commercial Products provided by PYRAMID to Client exclusively under this Agreement, or (b) Client Commercial Product regulatory submission, or
(c) regulatory authority audits exclusively related to Commercial Product, shall be paid by Client. Client shall reimburse PYRAMID for all such costs including, but not limited to, an hourly charge of [***] for persons responding to requests,
travel, lodging, meals, mileage, incidental expenses, reasonable attorneys’ fees for preparation of any person called to testify and associated fees and all other reasonable expenses associated with any such requests. 

 

	11.	SITE VISITS 

  

	 	11.1	In accordance with the Quality Agreement, Client may conduct Quality Assurance Site Compliance Audits each calendar year on a date mutually agreed upon by the Parties. The first (1st) day will be at no charge to Client and additional days will be charged at [***]. The Quality Assurance Site Compliance Audit includes the right to inspect any facility being used by PYRAMID
for the Services and to inspect all relevant records. Any additional audits specific to Commercial Product, including those by FDA or a Qualified Person, will be charged at [***]. 

 

	 	11.2	If Client is conducting a for cause audit or Parties agree that a major non-conformance is found and requires resolution and meetings necessary to verify corrective action has been taken as provided for in the Quality
Agreement, such activity will not result in a daily audit charge to Client. 

  

	 	11.3	In accordance with the Quality Agreement, Client may conduct a preparatory audit of PYRAMID in advance of an expected pre-approval inspection by a Regulatory Authority at no charge to the Client. 

 

	 	11.4	PYRAMID will co-operate fully with Client during audits performed under this section, including furnishing to Client copies of all requested documents. 

 

	 	11.5	PYRAMID will provide to Client access to PYRAMID’s facilities at no charge during execution of manufacturing Services under any Purchase Order, upon reasonable notice, for the purpose of providing technical
assistance or observing performance of the Services. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 12
 of 27

  

	12.	RECORDS 

  

	 	12.1	Unless stated otherwise in the Quality Agreement or Specifications, PYRAMID will, at its own expense, store all testing and quality control records relating to Commercial Products onsite for [***]; and for a period of
[***] offsite following completion of production of the Commercial Product. At the end of the [***], Client shall be notified to determine whether the records may be destroyed, provided to Client or continue to be stored at Client’s request or
expense. 

  

	 	12.2	PYRAMID will maintain, in accordance with Generally Accepted Accounting Principles and Practices, records reflecting the accuracy of PYRAMID’s charges, including invoices for compensation, and other information as
Client may reasonably require in connection with this Agreement (“Financial Records”). PYRAMID will preserve such documents, without receipt of additional compensation, for at least [***] after the date of the final payment.

  

	13.	PRODUCT REJECTION, RECALLS, ADVERSE EVENTS 

  

	 	13.1	In accordance with the Quality Agreement, Client will have the right to reject any Commercial Product Batch that has not been manufactured in compliance with PYRAMID’s warranty in Section 17 or does not meet
the established Specifications. 

  

	 	13.2	Client’s right of rejection will be exercised by delivery of written notice to PYRAMID in accordance with the procedures set out in the Quality Agreement or within [***] of receiving final Batch release
documentation, including a Certificate of Analysis, or in the case of Latent Defects due to a PYRAMID processing failure, shall be upon Client’s discovery any time during the shelf-life of the Commercial Product. For the purposes of this
Agreement, “Latent Defect” means a hidden flaw, weakness or imperfection of the Commercial Product unrelated to Client Materials which cannot be readily ascertained from the mere observation or a reasonable or customary inspection of the
such product and the root cause for any such Latent Defect must be proven or detected through product investigation. Any quantities of Commercial Product that are rejected pursuant to this section will be returned to PYRAMID at PYRAMID’s
expense, and either [***]. For the avoidance of doubt, PYRAMID shall not be liable for Latent Defects related to Client Materials. 

  

	 	13.3	 In accordance with the Quality Agreement, if PYRAMID disputes Client’s basis for rejecting a Commercial
Product, then PYRAMID must do so in writing within [***] of receiving a rejection notice from Client. The rejected Commercial Product will be tested by an independent GMP laboratory mutually agreed upon by the Parties

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 13
 of 27

  

	 	
and the independent laboratory’s determination will be final and binding on the Parties. The cost of such testing will be borne by PYRAMID if the independent laboratory confirms that the
product in question does not comply with PYRAMID’s warranty or other limitations, as provided for in Sections 17 and 22. Otherwise, the costs will be borne by Client. 

 

	 	13.4	In accordance with the Quality Agreement, Parties shall work collaboratively in a timely manner to initiate and process Recalls related to Commercial Product. If the cause of the Recall is related to PYRAMID’s
failure to comply with PYRAMID’s warranty in Section 17 or other provisions of this Agreement, PYRAMID shall reimburse Client for the cost of the Services and Client Materials used to manufacture the Commercial Product involved in the
Recall along with reasonable and documented Recall expenses, subject to limitations provided for in Section 22. 

  

	 	13.5	In accordance with the Quality Agreement, Parties shall work collaboratively in a timely manner to report and investigate Adverse Events and Product Complaints related to Commercial Product. 

 

	14.	INTELLECTUAL PROPERTY 

  

	 	14.1	Client will retain ownership of any Intellectual Property in the Specifications, Commercial Product formulation, Commercial Product manufacturing processes and Client Materials. Except for the limited purpose of
performing its obligations under this Agreement, PYRAMID is not granted any right, title or interest in any intellectual property owned or controlled by Client. 

  

	 	14.2	All right, title and interest in and to Intellectual Property produced, created, invented or developed by PYRAMID, including without limitation any improvements or modifications to the Client Materials, in performance
of formulation development, analytical testing and/or the manufacture of Commercial Product under a Purchase Order (all of the foregoing, “Developed IP”) will be considered a work-made-for-hire and belong to and owned by Client. To the
extent such Developed IP is not a work-made-for-hire under the applicable law, PYRAMID does assign and will assign all rights, title, and interest in and to such Developed IP to Client. PYRAMID agrees to reasonably cooperate and to complete, at
Client’s expense, any documents necessary for Client to file and prosecute applications for registration of such Developed IP, including filing and prosecuting patent applications with respect to such Developed IP, in Client’s name.
PYRAMID will, if deemed necessary or desirable by Client, on the same terms, execute an assignment of rights to Client with respect to such Developed IP, including any patent applications or patents. 

 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 14
 of 27

  

	15.	CONFIDENTIALITY 

  

	 	15.1	For purposes of this Agreement, the term “Information” will mean: 

  

	 	(a)	With respect to Client, the Specifications, assigned intellectual property, information relating to the Commercial Products and Client Materials and their manufacture including such information produced by PYRAMID in
performance of any Purchase Order, all written information which Client delivers to PYRAMID pursuant to this Agreement stamped or otherwise identified in writing on the document “Confidential,” and all oral information which Client
declares to be confidential and confirms such declaration in writing within [***] of disclosure; and 

  

	 	(b)	With respect to PYRAMID, all information relating to PYRAMID’s manufacturing procedures, techniques and/or facilities, which PYRAMID delivers to Client in performance of monitoring or auditing under this Agreement
stamped or otherwise identified in writing on the document “Confidential” if in writing, or if disclosed verbally, PYRAMID declares to be confidential and confirms such declaration in writing within [***] of disclosure. 

 

	 	15.2	A Party receiving Information (“Receiving Party”) from the other Party (“Disclosing Party”) will maintain the Information in confidence with the same degree of care it holds its own confidential
information. The Receiving Party will only use the Information for the purposes of performing its obligations or exercising its rights under this Agreement. The Receiving Party will not disclose the Information to any third party and will only
disclose the Information to its officers and employees that need the Information for the purposes of performing its obligations or exercising its rights under this Agreement. 

 

	 	15.3	The Receiving Party’s obligation of nondisclosure and the limitations upon the right to use the Information shall not apply to the extent that the Receiving Party can demonstrate that the Information:

  

	 	(a)	was in the possession of the Receiving Party prior to the time of disclosure; or 

  

	 	(b)	is or becomes public knowledge through no fault or omission of Receiving Party; or 

  

	 	(c)	is obtained by Receiving Party from a third party under no obligation of confidentiality to the Disclosing Party. All Information will be returned to the Receiving Party upon termination of this Agreement for any
reason, except for one copy, which Disclosing Party may use for the sole purpose of determining its continuing confidentiality obligation to the Disclosing Party under this Agreement; or 

 

	 	(d)	 if the Receiving Party is requested or ordered to disclose the Information in connection with a legal or
administrative proceeding, the Receiving Party will 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 15
 of 27

  

	 	
give the Disclosing Party prompt notice of such request. The Disclosing Party may seek an appropriate protective order or other remedy or waive compliance with the provisions of this Agreement or
both. If the Disclosing Party seeks a protective order or other remedy, the Receiving Party will cooperate with the Disclosing Party. If the Disclosing Party fails to obtain a protective order or waive compliance within the relevant provisions of
this Agreement, the Receiving Party will disclose only that portion of Information which its legal counsel determines it is required to disclose. 

  

	 	15.4	All information will be returned to the Receiving Party upon termination of this Agreement for any reason, except for one copy, which may be retained by the Receiving Party’s legal counsel for the sole purpose of
determining the Receiving Party’s continuing confidentiality obligation to the Disclosing Party under this agreement. 

  

	 	15.5	All confidentiality obligations of under this Agreement will survive the expiration or termination of this Agreement for a period of [***]. 

 

	16.	RELATIONSHIP  

  

	 	16.1	PYRAMID is an independent contractor and PYRAMID acknowledges that its personnel or employees are not employees of Client. Accordingly, neither PYRAMID nor its employees or personnel will (a) participate in Client
employee benefit plans nor receive any other compensation beyond that stated above, (b) have the power or authority to bind Client or to assume or create any obligation or responsibility, express or implied, on Client’s part or in
Client’s name, except as otherwise set forth in this Agreement, or (c) represent to any person or entity that PYRAMID, its personnel or any employee of PYRAMID has such power or authority. PYRAMID will remain solely liable for all aspects
of the employment of such persons including, without limitation, recruitment, hiring, firing, training, promotion, compensation, all payroll taxes and other deductions and all premiums or payments made for workers’ compensation coverage,
unemployment benefits or any other payments required by law to be made by employers for or on behalf of employees. 

  

	 	16.2	PYRAMID represents and warrants that it and its personnel, and employees are authorized to perform the Services and that neither it nor its personnel or employees will act in violation of any applicable immigration laws
or regulations. PYRAMID will indemnify Client against any and all claims, fines, penalties and/or attorneys’ fees incurred by Client for breach by PYRAMID of any immigration laws or regulations and of this warranty. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 16
 of 27

  

	17.	PYRAMID WARRANTIES 

  

	    	PYRAMID represents warrants and covenants that: 

  

	 	17.1	all Commercial Product supplied to Client under this Agreement will be manufactured in accordance with cGMP’s, Specifications and Regulatory Standards, and otherwise comply with the obligations set forth in
Section 2 above, and all Client Materials, PYRAMID supplied materials and consumables, in-process Commercial Product and finished and packaged Commercial Product shall be stored, processed, and shipped in accordance with cGMP’s,
Specifications and Regulatory Standards. 

  

	 	17.2	it is a corporation duly organized and existing in good standing under the laws of the state of its incorporation; 

  

	 	17.3	it has the right and authority to enter into and perform its obligations under this Agreement; 

  

	 	17.4	it will perform all of its obligations under this Agreement in accordance with all applicable governmental laws, rules and regulations; 

 

	 	17.5	it and its employees, affiliates, and agents have never been debarred, or convicted of a crime for which a person can be debarred (i) under Section 306(a) or (b) of the Generic Drug Enforcement Act of
1992, or (ii) for the award of United States of America Federal contracts; and none of PYRAMID’s employees, affiliates, or agents, according to PYRAMID’s best knowledge after due inquiry, has ever been threatened to be debarred or
indicted for a crime or otherwise engaged in conduct for which a person can be debarred, (i) under Section 306(a) or (b), or (ii) for the award of United States of America Federal contracts . PYRAMID agrees that it will promptly
notify Client upon learning of any such debarment, conviction, threat or indictment; and 

  

	 	17.6	the foregoing warranty is made to Client only and is not transferable to any agents or assigns of Client except to permitted assigns as described in Section 25.1. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THESE
TERMS AND CONDITIONS, PYRAMID MAKES NO REPRESENTATION AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

 

	18.	CLIENT WARRANTIES 

  

	    	Client represents, warrants, and covenants that: 

  

	 	18.1	it is a corporation duly organized and existing in good standing under the laws of the state of its incorporation; 

  

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 17
 of 27

  

	 	18.2	the Commercial Product and PYRAMID’s use of the processes or procedures described in the Specifications will not infringe the intellectual property rights of third parties; 

 

	 	18.3	it has the right and authority to enter into and perform its obligations under this Agreement; and 

  

	 	18.4	it will perform all of its obligations under this Agreement in accordance with all applicable governmental laws, rules and regulations. 

 

	19.	INDEMNIFICATION BY PYRAMID 

  

	 	19.1	PYRAMID will defend, indemnify and hold harmless Client and its Affiliates, and its or their officers, directors, shareholders, employees, agents and representatives from and against any and all liability, damage, loss,
cost or expense (including reasonable attorney’s fees, costs and amounts paid in settlement) (collectively, “Losses”) resulting from any third party claim made or suit brought against Client or any such persons arising out of
(a) PYRAMID’s breach of any of its representations, warranties or covenants in Section 17; (b) the use by Client of any Commercial Product or Special Product supplied by PYRAMID under this Agreement that does not comply with its
applicable Specifications, or (c) infringement of any third party Intellectual Property to the extent such infringement is not caused by or attributable to Client Materials. 

 

	 	19.2	Upon receipt of notice of any such claim or suit, Client will promptly notify PYRAMID thereof and will permit PYRAMID, at its cost, to handle and control such claim or suit; provided, however, that PYRAMID may not
settle or compromise any claim or consent to the entry of any judgment regarding which indemnification is being sought hereunder without Client’s prior written consent. Client will have the right to participate in the defense of such claim or
suit at its own expense. Client shall afford PYRAMID all reasonable assistance (at PYRAMID’s cost and expense) and will make no admission prejudicial to the defense of such claim or suit. 

 

	 	19.3	The foregoing indemnification obligation will not apply to any claim or suit to the extent it arises directly out of Client’s negligence, willful misconduct or breach of any term, representation, warranty or
covenant contained in this Agreement. 

  

	20.	INDEMNIFICATION BY CLIENT 

  

	 	20.1	 Client will defend, indemnify and hold harmless PYRAMID and its Affiliates, and its or their officers, directors,
shareholders, employees, agents and representatives from and against any and all liability, damage, loss, cost or expense (including reasonable attorney’s fees, costs and amounts paid in settlement) (collectively, “Losses”) resulting
from any third party claim made or suit brought against PYRAMID or any such persons arising out of (a) Client’s breach of any of its 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 18
 of 27

  

	 	
representations, warranties or covenants in Section 18; (b) the use by Client of any Commercial Product or Special Product supplied by PYRAMID under this Agreement that complies with
its applicable Specifications, or (c) infringement of any third party Intellectual Property to the extent such infringement is caused by or attributable to Client Materials. 

 

	 	20.2	Upon receipt of notice of any such claim or suit, PYRAMID will promptly notify Client thereof and will permit Client, at its cost, to handle and control such claim or suit. PYRAMID will have the right to participate in
the defense of such claim or suit at its own expense. PYRAMID will afford Client all reasonable assistance (at Client’s cost and expense) and will make no admission prejudicial to the defense of such claim or suit. 

 

	 	20.3	The foregoing indemnification obligation will not apply to any claim or suit to the extent it arises directly out of PYRAMID’s negligence, willful misconduct or breach of any term, representation, warranty or
covenant contained in this Agreement. 

  

	21.	INSURANCE  

 At all times commencing with the Effective Date of the signed Agreement,
Client shall maintain adequate product or general liability insurance and shall maintain adequate property insurance to appropriately cover the replacement cost of Client Materials. At all times commencing with the Effective Date of the signed
Agreement, PYRAMID shall carry insurance adequate to cover its interest or liabilities hereunder including, but not limited to, worker’s compensation, general liability, and property insurance sufficient to cover damage to Pyramid materials and
Client Materials, as further defined in Section 8.3 and such coverage shall be a [***]. 
  

	22.	LIMITATION OF LIABILITY 

 Except for breach of the Confidentiality Obligations, or
liability for infringement or misappropriation of their party Intellectual Property rights, each Party’s liability under this Agreement shall be [***]. Neither Party shall be liable under this Agreement, whether in tort, contract or otherwise,
for any indirect, incidental or consequential losses or any punitive or exemplary damages. 
  

	23.	PUBLICITY 

  

	 	23.1	No press releases or other statements in connection with this Agreement intended for use in the public or private media shall be made by Client or PYRAMID without the prior written consent of the other Party. If either
Party is required by law or governmental regulation to describe its relationship to the other, it will promptly give the other Party notice with a copy of any disclosure it proposes to make. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 19
 of 27

  

	 	23.2	In addition, PYRAMID will not use Client’s name in connection with any products, services, promotion, or advertising without Client’s prior written permission. 

 

	24.	TERM AND TERMINATION  

  

	 	24.1	This Agreement will end on completion of the Services set forth herein or under the last Purchase Order placed within [***] from the Effective Date. This Agreement shall automatically continue after the Initial Term for
successive terms of [***] each unless either Party gives written notice to the other Party of its intention to terminate this agreement giving [***] notice. 

  

	 	24.2	Either Party at its sole option may immediately terminate this Agreement upon written notice, but without prior advance notice, to the other Party in the event that (i) the other Party is declared insolvent or
bankrupt by a court of competent jurisdiction; (ii) a voluntary petition of bankruptcy is filed in any court of competent jurisdiction by such other Party; or (iii) this Agreement is assigned by such other Party for the benefit of
creditors. 

  

	 	24.3	If either Party breaches this Agreement, the other Party may terminate this agreement if the breaching Party does not cure the breach within [***] of written notice of the same. Termination will be without prejudice to
any rights that may have been accrued to either Party before termination. Cure of a breach under this Section 24.3 will not be available under the following Sections 24.4-24.7. 

 

	 	24.4	Client may terminate this Agreement upon [***] written notice in the event that FDA or any other governmental agency takes any action, or raises any objection, that prevents the Client from importing, exporting,
purchasing or selling Commercial Product. 

  

	 	24.5	Client may terminate this Agreement upon [***] written notice in the event that PYRAMID has [***] within the same Calendar Year. 

  

	 	24.6	Client may terminate this Agreement upon [***] written notice in the event that PYRAMID does not have suitable Total Available Capacity to deliver Client’s Rolling Forecast or Long-Term Forecast. 

 

	 	24.7	Client may terminate this Agreement upon [***] written notice in the event that PYRAMID and Client cannot agree on revised pricing resulting from any requested Specification change as further defined in Section 5.

  

	 	24.8	Except for expiration or termination of this Agreement for reasons stated in Sections 24.2 and 24.3, Client shall have the option to secure and PYRAMID shall agree to supply, an additional inventory of Commercial
Product [***] according to a delivery schedule agreeable to both Parties. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 20
 of 27

  

	 	24.9	Upon expiration or termination of this Agreement for any reason, PYRAMID will return, at Client’s expense, all Client Materials, Client equipment and Client documentation. In addition, the Parties will return to
each all copies of the other Party’s Information except for one copy that may be retained for the sole purpose of determining continuing obligations under Section 15. 

 

	 	24.10	Client shall provide at least [***] prior notice if it intends to no longer order a Commercial Product due to discontinuance of the Commercial Product in the market. 

 

	25.	GENERAL 

  

	 	25.1	Assignment; Subcontractors. Neither Party will transfer or assign its rights or obligations under this Agreement, in whole or in part, without the other Party’s prior written permission; provided, however, that
Client may assign its rights and obligations under this Agreement to any Affiliate without PYRAMID’s prior consent but must give PYRAMID written notice of such assignment within [***] following the assignment. PYRAMID may not utilize
subcontractors to perform any part of the Services without prior written authorization by Client. All assignees must comply with the terms of this Agreement. 

  

	 	25.2	[***]. 

  

	 	25.3	Entire Agreement; Amendments. The provisions, terms and conditions of this Agreement (including its Schedules and any subsequent Purchase Orders) constitute the entire agreement of the Parties with regard to the subject
matter of this Agreement and supersede any prior agreements whether oral or written. No waiver, modification, change or amendment of any of the provisions of this Agreement shall be valid unless in writing and signed by the Party against whom such
claimed waiver, modification, change or amendment is sought to be enforced. The terms of this Agreement shall supersede any subsequent Schedules or Purchase Orders in the event of inconsistencies with the terms of this Agreement. 

 

	 	25.3	Notices. All notices, requests, demands and other communications required or permitted to be given hereunder will be in writing and will be deemed to have been given (a) when received, if delivered in person, or
(b) three (3) business days following the mailing thereof, if mailed by certified first class mail, postage prepaid, return receipt requested, in any such case as follows: 

If to Client: 

Xeris Pharmaceuticals, Inc. 

180 N. LaSalle Street, Suite 1800 

Chicago, Illinois 6060 

Attn.: COO & General Counsel 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 21
 of 27

  

			
	 If to PYRAMID:
	 	 PYRAMID Laboratories, Inc.
 3598 Cadillac
Ave.
 Costa Mesa, California 92626
 Attn.: President &
CEO

  

	 	25.4	Severability. If any term or provision of this Agreement is invalid or unenforceable, the remainder of this Agreement shall be unaffected thereby and each remaining term or provision of this Agreement is valid and will
be enforceable to the fullest extent permitted by law. 

  

	 	25.5	Waiver. The failure of either Party to insist upon strict observation or performance of any provision of this Agreement, or to exercise any right or remedy shall not impair or waive any such right or remedy in the
future. Every right and remedy given by this Agreement to the Parties may be exercised from time to time as often as appropriate. All remedies, either under this Agreement or by law or otherwise afforded, will be cumulative and not alternative.

  

	 	25.6	Force Majeure. Neither Party will be liable nor deemed to be in default for any delay or failure in performance under this Agreement or other interruption of service or employment deemed resulting directly or indirectly
from Acts of God, civil or military authority, acts of public enemy, war, accident, fire, explosion, earthquake, flood, failure of transportation, strike, or other work interruption by either party’s employees or any similar or dissimilar cause
beyond the reasonable control of either Party. 

  

	 	25.7	Binding Effect. This Agreement will be binding upon and will inure to the benefit of Client and PYRAMID, their respective successors and permitted assigns. 

 

	 	25.8	Arbitration. Any dispute, controversy or claim arising out of or related to this Agreement, or the breach thereof, shall be settled by binding arbitration in accordance with the Commercial Rules of the American
Arbitration Association, and judgment upon any arbitration award rendered hereunder may be entered in any court having jurisdiction. Each Party shall select one (1) neutral arbitrator from a list provided by the American Arbitration Association
and those two arbitrators shall select a third arbitrator from the list. The arbitration process shall take place in Delaware, or such other place as the Parties may hereafter agree. The prevailing Party shall have the costs for the arbitration,
including attorneys’ fees, paid by the non-prevailing Party. 

  

	 	25.9	Governing Law. This Agreement is to be construed and determined under the laws of the State of Delaware. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 22
 of 27

  

	 	25.10	Headings. The headings of this Agreement are inserted merely for convenience and ease of reference and will not affect or modify the meaning of any of the terms, covenants or conditions of this Agreement.

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 23
 of 27

  

 IN WITNESS WHEREOF, the parties have executed this Agreement in duplicate originals by their duly
authorized representatives. 
  

									
	PYRAMID Laboratories Inc.	 		 	Xeris Pharmaceuticals, Inc.
					
	By:	 	  
	 	            	 	By:	 	  

	Name:	 	Medhat Gorgy	 		 	Name:	 	Paul Edick
	Title:	 	President& CEO	 		 	Title:	 	CEO
	Date:	 		 		 	Date:	 	

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 24
 of 27

  

 Schedule A 

Batch Size, Dosage, Yield*, Volume, Pricing 
  

					
	 [***]
	  		  	
			
	 [***]
	  		  	
			
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  		  	
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  		  	
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  		  	
			
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
			
	 [***].
	  		  	

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 25
 of 27

  

 Schedule A (continued) 

Batch Size, Dosage, Yield, Volume Pricing 

Pricing Assumptions: 
  

	1.	Standard Batch [***]. 

  

	2.	Standard batch size estimates based on [***] theoretical yield per dosage; yield assumptions and batch sizes shall be adjusted annually based on actual production history. 

 

	3.	Batch size/yield/price independent [***]. 

  

	4.	Pricing subject to annual adjustments as defined under Section 3.3.2, [***]. 

  

	5.	Pricing for Validation Batches shall be adjusted as defined under Section 3.3.3 [***]. 

  

	6.	Price includes [***]. 

  

	7.	Price includes [***]. 

  

	8.	Price excludes [***]. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 26
 of 27

  

 Schedule B 

Client Materials 
  

							
	 Name
	  	 Description
	  	 Client Specification
	  	 
	 [***]
	  	[***]	  	[***]	  	
				
	 [***]
	  	[***]	  	[***]	  	
		  	[***]	  		  	
		  	[***]	  		  	
		  	[***]	  		  	
				
	 [***]
	  	[***]	  	[***]	  	
		  	[***]	  		  	
		  	[***]	  		  	
		  	[***]	  		  	
				
	 [***]
	  	[***]	  	[***]	  	
		  	[***]	  		  	
		  	[***]	  		  	
				
	 [***]
	  	[***]	  		  	
		  	[***]	  	[***]	  	

 Specifications for each Client Material shall be updated from time to time as required in accordance with provisions of the
Quality Agreement. 

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax) 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED 
  

							
	

	  	 	  	 Document No:

Revision:
 Revision Date:

Replaces:
 Page:
	  	 MSA-XPI

00
 05/01/18

NA
 
 27
 of 27

  

 Schedule C 

Commercial Products 
  

							
	 Client Part Number
	  	 Description
	  	 	  	 
	[***]	  	[***]	  		  	
				
	[***]	  	[***]	  		  	
				
	[***]	  	[***]	  		  	
				
	[***]	  	[***]	  		  	

  
 3598 Cadillac Avenue
• Costa Mesa, CA 92626 • 714-435-9800 • 714-435-9585 (Fax)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]